Bladder Cancer Clinical Trial
Official title:
HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy
Verified date | March 2010 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above
normal body temperature. Drugs used in chemotherapy, such as mitomycin C and epirubicin
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Biological therapies, such as bacillus
calmette-guerin (BCG) and interferon alfa, may stimulate the immune system in different ways
and stop tumor cells from growing. It is not yet known whether giving hyperthermia together
with mitomycin C is more effective than giving BCG or standard therapy as second-line
therapy in treating patients with recurrent bladder cancer.
PURPOSE: This randomized phase III trial is studying how well hyperthermia given together
with mitomycin C works compared with BCG or standard therapy as second-line therapy in
treating patients with recurrent bladder cancer.
Status | Recruiting |
Enrollment | 242 |
Est. completion date | |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of non-muscle invasive bladder cancer - Recurrent disease after undergoing induction or maintenance therapy with bacillus Calmette-Guérin (BCG), meeting any 1 of the following criteria: - Stage Ta or T1 disease (grade 2 or 3) - Carcinoma in situ with stage Ta or T1 disease (grade 1, 2, or 3) - Carcinoma in situ alone - Has undergone a second resection of all T1 disease to exclude muscle invasive disease - No urothelial cell carcinoma (UCC) = T2 - No recurrence of grade 1 UCC following BCG induction therapy - No UCC involving the prostatic urethra or upper urinary tract PATIENT CHARACTERISTICS: - WHO performance status 0-4 - WBC = 3.0 x 10^9/L - Absolute neutrophil count = 1.5 x 10^9/L - Hemoglobin = 10 g/dL - Platelet count = 100 x 10^9/L - Serum creatinine < 1.5 times upper limit of normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Normal kidneys and ureters on imaging CT scan within the past 12 months - Available for long-term follow-up with a life expectancy of the duration of the trial - Must be fit and willing to undergo a full or partial cystectomy - No known or suspected reduced bladder capacity (< 250 mL) - No significant bleeding disorder - No other malignancy within the past 5 years except nonmelanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix, or DCIS/LCIS of the breast - No known allergy to mitomycin or bacillus Calmette-Guérin (BCG), or previously withdrawn from BCG treatment due to a related adverse event (e.g., systemic infection) - No active or intractable urinary tract infection - No urethral stricture or any situation impeding the insertion of a 20F catheter - No bladder diverticula > 1 cm - No significant urinary incontinence - No concurrent implanted electronic devices (e.g., cardiac pacemakers) or metallic implants within the pelvis, lower torso, spine, hip, or upper femur - No immunocompromised state for any reason PRIOR CONCURRENT THERAPY: - At least 6 months since prior intravesical chemotherapy, except for single instillation post-transurethral resection - No prior pelvic irradiation - No prior hyperthermia in combination with intravesical mitomycin - Concurrent participation in other studies allowed - No current or long-term use of corticosteroids - No concurrent chemotherapy |
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Basingstoke and North Hampshire NHS Foundation Trust | Basingstoke | England |
United Kingdom | Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust | Birmingham | England |
United Kingdom | University Hospital of Wales | Cardiff | Wales |
United Kingdom | Leeds Cancer Centre at St. James's University Hospital | Leeds | England |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | England |
United Kingdom | St. George's Hospital | London | England |
United Kingdom | University College of London Hospitals | London | England |
United Kingdom | South Manchester University Hospital | Manchester | England |
United Kingdom | James Cook University Hospital | Middlesbrough | England |
Lead Sponsor | Collaborator |
---|---|
Cancer Research Campaign Clinical Trials Centre |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease-free survival time | No | ||
Primary | Complete response rate at 3 months in patients with carcinoma in situ | No | ||
Secondary | Recurrence-free survival time | No | ||
Secondary | Progression-free survival time | No | ||
Secondary | Overall survival time | No | ||
Secondary | Disease-specific survival time | No | ||
Secondary | Safety and tolerability | Yes | ||
Secondary | Quality of Life | No | ||
Secondary | Cost effectiveness | No | ||
Secondary | Biomarkers of response to standard and investigational treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |